K
Karthik V. Giridhar
Researcher at Mayo Clinic
Publications - 51
Citations - 611
Karthik V. Giridhar is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 12, co-authored 26 publications receiving 453 citations. Previous affiliations of Karthik V. Giridhar include University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
A quantitative synthesis of disparities in the inclusion of racial/ethnic minorities and older women in breast cancer trials.
Mahnoor Islam,Syed Arsalan Ahmed Naqvi,M. D. Bin Zafar,Ahsan Ayaz,Yusra Saleem,Atiqa Khalid,Muhammad Hisham Khan Wazir,Hafsah Ijaz,Karthik V. Giridhar,Siddhartha Yadav,Brenda Ernst,Irbaz Bin Riaz +11 more
TL;DR: In this article , the authors analyzed all phase 2/3 trials for age disparity and trials recruiting from the US for racial/ethnic disparity amongst breast cancer RCTs (1990-2021).
Journal ArticleDOI
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).
Rudolph M. Navari,Jennifer Le-Rademacher,Kathryn J. Ruddy,Heshan Liu,Elizabeth S Harlos,Adedayo A. Onitilo,Karthik V. Giridhar,Pavan S. Reddy,Selina L. Chow,Flavio Kruter,George Raptis,Charles L. Loprinzi +11 more
TL;DR: A prospective double-blind, placebo-controlled clinical trial was developed to evaluate the value of an NK-1 receptor antagonist for preventing nausea and vomiting resulting from highly emetogenic chemotherapy when an olanzapine-based antiemetogenic regimen was used as discussed by the authors .
Journal ArticleDOI
Abstract OT1-04-02: Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial
Tufia C. Haddad,Vera J. Suman,Karthik V. Giridhar,Alvaro Moreno-Aspitia,Donald W. Northfelt,Brenda Ernst,Kostandinos Sideras,Ciara C. O’Sullivan,Zeruesenay Desta,Jodi L. Taraba,Barbara Goodnature,Matthew P. Goetz,Liewei Wang,James N. Ingle +13 more
TL;DR: For example, this article found a significant 3.0-fold increase in risk of an early breast cancer (EBC) event for those taking anastrozole with levels of estrone (E1) ≥ 1.3 pg/mL and estradiol (E2) ≥ 0.5pg/mL.
Journal ArticleDOI
Abstract P5-13-22: Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)
Ciara C. O’Sullivan,Jun-mei He,Jason P. Sinnwell,Vera J. Suman,Krishna R. Kalari,Peter T. Vedell,Ann M. Moyer,Xiaojia Tang,Kevin J. Thompson,Abraham D Eyman Casey,Alvaro Moreno-Aspitia,Donald W. Northfelt,Minetta C. Liu,Tufia C. Haddad,Saranya Chumsri,Brendan P. McMenomy,Prema P. Peethambaram,Kathryn J. Ruddy,Karthik V. Giridhar,Roberto A. Leon-Ferre,Mattias Bergqvist,Adrian Nordmark,Richard M. Weinshilboum,Liewei Wang,Matthew P. Goetz +24 more
TL;DR: A secreted biomarker of proliferation (TK1) obtained prior to initiating CDK4/6i and ET for the treatment of HR+ MBC is reported, and high levels of TKa are associated with inferior PFS, whereas pts with low TKa levels pretreatment have superior PFS.
Journal ArticleDOI
Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance)
Kostandinos Sideras,David W. Hillman,Karthik V. Giridhar,Brenda Ginos,Richard C. Tenglin,Heshan Liu,Beiyun Chen,Winston Tan,G. G. Gross,Rex B. Mowat,Amylou C. Dueck,Edith A. Perez,Alvaro Moreno-Aspitia +12 more
TL;DR: Pixantrone has insufficient activity in the second- and third-line MBC setting, however, it appears to have limited cardiotoxicity.